About Us
Fresenius Kabi at a glance
Our product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the medical devices for administering these products. Within transfusion technologies, Fresenius Kabi offers products for collection and processing of blood components and for therapeutic treatment of patient blood by apheresis systems. In the field of biosimilars, we develop products with a focus on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection of blood components and extracorporeal therapies.
Fresenius Kabi employs more than 42,000 people worldwide.
With our corporate philosophy of "caring for life", we are committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.
In 2022, the company reported sales of more than €7.8 billion. Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA healthcare group.
Key Figures
| € in millions | 2022 | 2021 |
|---|---|---|
| Sales | 7,850 | 7,193 |
| EBITDA1 | 1,576 | 1,601 |
| EBIT1 | 1,080 | 1,153 |
| Net Income1,2 | 780 | 778 |
| Employees (Dec 31) | 42,063 | 41,397 |
1 Before special items
2 Net income atrributable to shareholders of Fresenius SE & Co. KGaA